Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation

Bibliography

• KOWALSKI H, ABELMANN WH: The cardiac output at rest in Laennec's cirrhosis. CM. Invest. (1953) 32:1025–1033.
   PubMed Web of Science ®Google Scholar
• MURRAY JF, DAWSON AM, SHERLOCK S: Circulatory changes in chronic liver disease. Am. j Med (1958) 24:358–367.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, ARROYO V, BERNARDI M, EPSTEIN M, HENRIKSEN JH, RODES J: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 8(5):1151–1157.
   PubMed Web of Science ®Google Scholar
• ••An important presentation of unifyinghypothesis explaining the development of many of the complications of cirrhosis.
   Google Scholar
• KONTOS HA, SHAPIRO WMAUCK HP, PATTERSON JL: Generaland regional alterations in cirrhosis of theliver. Am. j Med. (1964) 37:526–535.
   PubMed Web of Science ®Google Scholar
• BRADLEY SE: Variations in hepatic bloodflow in man during health and disease.N. Engl. J. Med. (1949) 240:456–461.
   PubMed Web of Science ®Google Scholar
• WYNNE HA, COPE LH, MUTCH E, RAWLINS MD, WOODHOUSE KW, JAMES OF: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 9(2):297–301.
   PubMed Web of Science ®Google Scholar
• WANLESS IR, WONG E BLENDIS LM, GREIG P, HEATHCOTE PJ, LEVY G: Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology (1995) 21(5):1238–1247.
   PubMed Web of Science ®Google Scholar
• GROSSMAN HJ, GROSSMAN VL, BHATHAL PS: Enhanced vasoconstrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. Gastroenterol. Hepatol. (1992) 7(3)283–287.
   Google Scholar
• BHATHAL PS, GROSSMAN HJ: Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. I Hepatol. (1985) 1(4)325–337.
   Google Scholar
• WIEST R, GROSZMANN RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: too much not enough. Hepatology (2002) 35(2):478–491.
   PubMed Web of Science ®Google Scholar
• •A good discussion of the role of the vasodilator NO in cirrhosis.
   Google Scholar
• ROCKEY DC, CHUNG JJ: Reduced nitricoxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology(1998) 114(2):344–351.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SG, WESTABY D: Management of variceal haemorrhage.Br. Med. J. (1994) 308(6938):1213–1217.
   Google Scholar
• GINES E FERNANDEZ-ESPARRACH G, ARROYO V, RODES J: Pathogenesis ofascites in cirrhosis. Semir]. Liver Dis. (1997) 17(3):175–189.
   PubMedGoogle Scholar
• GINES P, MARTIN PY,NIEDERBERGER M : Prognostic significance of renal dysfunction in cirrhosis. Kidney Int. Suppl. (1997) 61:S77–S82.
   Google Scholar
• SUCH J, RUNYON BA: Spontaneous bacterial peritonitis. Chia. Infect. Dis. (1998) 27(4):669–674; Quiz 675–676.
   Google Scholar
• BICHET DG, VAN PUTTEN VJ, SCHRIER RW: Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.N Engl. j Med. (1982) 307(25):1552–1557.
   Google Scholar
• SCHRIER RW, NIEDERBERGER M, WEIGERT A, GINES P: Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semir]. Liver Dis. (1994) 14(1):14–22.
   PubMed Web of Science ®Google Scholar
• GINES A, ESCORSELL A, GINES P et al.: Incidence predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 105 (1):229–236.
   PubMed Web of Science ®Google Scholar
• MERKEL C, BOLOGNESI M,SACERDOTI D etal.: The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.Hepatology (2000) 32(5)930–934.
   Google Scholar
• KRAVETZ D, SIKULER E, GROSZMANN RJ: Splanchnic and systemic hemodynamics in portalGROSZMANN RJ: fl-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good the bad the ugly. Gastroenterology (1997) 113(5):1794–1797.GARCIA-PAGAN JC, VILLANUEVA C, VILA MC et al: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive 13-blockers. Gastroenterology (2001) 121(4):908–914.BORRONI G, SALERNO F,CAZZANIGA M et al: Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites.Hepatol (2002) 37(3):315–321.KROEGER RJ, GROSZMANN RJ: The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology (1985) 5(3):425–430.MERKEL C, MARIN R, ENZO E etal.: Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per Eipertensione portale (GTIP). Lancet (1996) 348(9043):1677–1681.MERKEL C, GATTA A, DONADA C et al.: Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology (1995) 22(3):808–813.MERKEL C, SACERDOTI D, BOLOGNESI M etal.: Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the fl-blocker alone. Hepatology (1997) 26(1):34–39.GOURNAY J, MASLIAH C, MARTIN T, PERRIN D, GALMICHE JP: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology (2000) 31(6):1239–1245. hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology (1986) 90(5 Pt 0:1232–1240.
   Google Scholar
• HILLON E LEBREC D, MUNOZ C, JUNGERS M, GOLDFARB G, BENHAMOU JP: Comparison of the effects of a cardioselective and a nonselective 13-blocker on portal hypertension in patients with cirrhosis. Hepatology (1982) 2(5):528–531.
   PubMed Web of Science ®Google Scholar
• MILLS PR, RAE AP, FARAH DA, RUSSELL RI, LORIMER AR, CARTER DC: Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut (1984) 25(1):73–78.
   PubMed Web of Science ®Google Scholar
• D'AMICO G, PAGLIARO L, BOSCH J: Pharmacological treatment of portal hypertension: an evidence-based approach. Semin. Liver Dis. (1999) 19(4):475–505.
   PubMed Web of Science ®Google Scholar
• ••This is a thorough meta-analytical reviewof the available evidence supporting treatment choices in the management of portal hypertension.
   Google Scholar
• D'AMICO G, PAGLIARO L, BOSCH J: The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 22(1):332–354.
   PubMed Web of Science ®Google Scholar
• ZOLI M C, MERKEL D, MAGALOTTI et al: Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am. j Gastroenterol (2000) 95(2):503–508.
   PubMed Web of Science ®Google Scholar
• BERNARD B, LEBREC D, MATHURIN E OPOLON EPOYNARD T: fl-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 25(1):63–70.
   PubMed Web of Science ®Google Scholar
• ••A meta-analysis of the evidence supportingthe use of 13-blockers in patients with portal hypertension for secondary prevention of variceal bleeding.
   Google Scholar
• GONZALEZ SUAREZ B, GUARNER C, MINANA J et al: Pharmacological treatment of portal hypertension contributes to prevent community-acquired spontaneous bacterial peritonitis (SBP)Hepatol (2000) 32:42A.
   Google Scholar
• PEREZ-PARAMO M, MUNOZ J, ALBILLOS A et al.: Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology (2000) 31(1):43–48.
   PubMed Web of Science ®Google Scholar
• LUI HF, STANLEY AJ, FORREST EH et al.: Primary prophylaxis of varicealhemorrhage: a randomized controlled trial39.comparing band ligation propranolol and isosorbide mononitrate. Gastroenterology (2002) 123(3):735–744.
   Google Scholar
• VILLANUEVA C, BALANZO J,NOVELLA MT et al.: Nadolol plus40.isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl. I Med. (1996) 334(25):1624–1629.
   Google Scholar
• VILLANUEVA C, MINANA J, ORTIZ J41.etal.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl. j Med. (2001) 345(9):647–655.
   Google Scholar
• BANARES R, MOITINHO E,42.PIQUERAS B etal.: Carvedilol a new nonselective beta-blocker with intrinsic anti-a1-adrenergic activity has a greater portal hypotensive effect than propranololin patients with cirrhosis. Hepatology (1999)43.30(1):79–83.
   Google Scholar
• BANARES R, MOITINHO E,MATILLA A et al.: Randomizedcomparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.Hepatology (2002) 36(6):1367–1373.44.
   Google Scholar
• GARCIA-PAGAN JC, NAVASA M, BOSCH J, BRU C, PIZCUETA P,RODES J: Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology (1990) 11(2):230–238.45.
   Google Scholar
• GARCIA-TSAO G, GRACE ND,GROSZMANN RJ et al: Short-term effects of propranolol on portal venous pressure. Hepatology (1986) 6(1):101–106.
   PubMed Web of Science ®Google Scholar
• HAYES PC, WESTABY D, WILLIAMS R:Effect and mechanism of action of46.isosorbide-5-mononitrate. Gut (1988) 29(6):752–755.
   Google Scholar
• ANGELICO M, CARLI L, PIAT C etal.: Isosorbide-5-mononitrate versuspropranolol in the prevention of firstbleeding in cirrhosis. Gastroenterology47. (1993) 104(5):1460–1465.
   Google Scholar
• ANGELICO M, CARLI L, PIAT C, GENTILE S, CAPOCACCIA L: Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-termsurvival in cirrhosis. Gastroenterology (1997)48.113(5):1632–1639.
   Google Scholar
• GROSZMANN RJ: •-adrenergic blockersand nitrovasodilators for the treatment ofportal hypertension: the good the bad theugly. Gastroenterology (1997) 113(5):1794–1797.
   PubMed Web of Science ®Google Scholar
• GARCIA-PAGAN JC, VILLANUEVA C,VILA MC et al.: Isosorbide mononitrate inthe prevention of first variceal bleed inpatients who cannot receive •-blockers.Gastroenterology (2001) 121(4):908–914.
   Google Scholar
• BORRONI G, SALERNO F,CAZZANIGA M et al.: Nadolol is superiorto isosorbide mononitrate for theprevention of the first variceal bleeding incirrhotic patients with ascites.J. Hepatol. (2002) 37(3):315–321.
   Google Scholar
• KROEGER RJ, GROSZMANN RJ: Theeffect of the combination of nitroglycerinand propranolol on splanchnic and systemichemodynamics in a portal hypertensive ratmodel. Hepatology (1985) 5(3):425–430.
   PubMed Web of Science ®Google Scholar
• MERKEL C, MARIN R, ENZO E et al.:Randomised trial of nadolol alone or withisosorbide mononitrate for primaryprophylaxis of variceal bleeding in cirrhosis.Gruppo-Triveneto per L•ipertensioneportale (GTIP). Lancet (1996) 348(9043):1677–1681.
   Google Scholar
• MERKEL C, GATTA A, DONADA Cet al.: Long-term effect of nadolol ornadolol plus isosorbide-5-mononitrate onrenal function and ascites formation inpatients with cirrhosis. GTIP GruppoTriveneto per l•Ipertensione Portale.Hepatology (1995) 22(3):808–813.
   Google Scholar
• MERKEL C, SACERDOTI D,BOLOGNESI M et al.: Hemodynamicevaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patientswith insufficient response to the �-blockeralone. Hepatology (1997) 26(1):34–39.
   Google Scholar
• GOURNAY J, MASLIAH C, MARTIN T,PERRIN D, GALMICHE JP: Isosorbidemononitrate and propranolol comparedwith propranolol alone for the prevention ofvariceal rebleeding. Hepatology (2000) 31(6):1239–1245.
   PubMed Web of Science ®Google Scholar
• CIRERA I, FEU F, LUCA A et al: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology (1995) 22(1):106–111.
   PubMed Web of Science ®Google Scholar
• CHATILA R, FERAYORNI L, GUPTA T, GROSZMANN RJ: Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology (2000) 31(3):572–576.
   PubMed Web of Science ®Google Scholar
• WIEST R, TSAI MH, GROSZMANN RJ: Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology (2001) 120(4):975–983.
   PubMed Web of Science ®Google Scholar
• ALBILLOS A, ROSSI I, IBORRA J et al: Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. I Hepatol (1994) 21(1):88–94.
   Web of Science ®Google Scholar
• GOTZSCHE PC, GJORUP I,BONNEN H, BRAHE NE, BECKER U, BURCHARTH F: Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. Br. Med. 1 (1995) 310(6993):1495–1498.
   Google Scholar
• BURROUGHS AK, MCCORMICK PS, HUGHES MD, SPRENGERS D, D'HEYGERE E MCINTYRE N: Randomized double-blind placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology (1990) 99(5):1388–1395.
   Google Scholar
• ESCORSELL A, BORDAS JM, DEL ARBOL LR et al.: Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. I Hepatol (1998) 29(5):779–788.
   Google Scholar
• CORLEY DA, CELLO JP, ADKISSON W, KO WE KERLIKOWSKE K: Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology (2001) 120(4):946–954.
   PubMed Web of Science ®Google Scholar
• AVGERINOS A, NEVENS E RAPTIS S, FEVERY J: Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet (1997) 350(9090):1495–1499.
   PubMed Web of Science ®Google Scholar
• BOSCH J, BORDAS JM, MASTAI R et al.: Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology (1988) 8(4):861–865.
   PubMed Web of Science ®Google Scholar
• BOSCH J, GROSZMANN JR,GARCIA-PAGAN JR et al: Association of transdermal nitroglycerin to vasopressin infusion in the treatment of varicealhemorrhage: a placebo-controlled clinical trial. Hepatology (1989) 10(6):962–968.
   PubMed Web of Science ®Google Scholar
• IOANNOU GN, DOUST J,ROCKEY DC: Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment. Pharmacol Ther. (2003) 17(1):53–64.
   PubMed Web of Science ®Google Scholar
• ESCORSELL A, RUIZ L,DEL ARBOL LR, PLANAS R etal.: Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 32(3):471–476.
   Google Scholar
• GOULIS J, PATCH D,BURROUGHS AK: Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 353(9147):139–142.
   PubMed Web of Science ®Google Scholar
• SORIANO G, GUARNER C, TOMAS A et al: Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology (1992) 103(4):1267–1272.
   PubMed Web of Science ®Google Scholar
• BERNARD B, GRANGE JD, KHAC EN, AMIOT X, OPOLON P, POYNARD T: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 29(6):1655–1661.
   PubMed Web of Science ®Google Scholar
• BOSCH J V ARROYO A BETRIU et al: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology (1980) 78(1):92–99.
   PubMed Web of Science ®Google Scholar
• CHIANG HT, CHENG JS, LIN M, TSENG WS, CHANG JM, LAI KH: Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. I Gastroenterol. Hepatol (1995) 10(3):256–260.
   PubMed Web of Science ®Google Scholar
• PARIENTE EA, BATAILLE C, BERCOFF E, LEBREC D: Acuteeffects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology (1985) 88(5 Pt 1):1255–1259.
   Google Scholar
• ARROYO V, BOSCH J, MAURI M, RIBERA E NAVARRO-LOPEZ F, RODES J: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur. I Gun. Invest. (1981) 11(3):221–229.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER AW, KALK JF, KLEIN CP: Effect of losartan an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology (1999) 29(2):334–339.
   PubMed Web of Science ®Google Scholar
• SCHEPKE M, WERNER E, BIECKER E etal.: Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 121(2):389–395.
   Google Scholar
• GONZALEZ-ABRALDES J,ALBILLOS A, BANARES R et al: Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.Gastroenterology (2001) 121(2):382–388.
   PubMed Web of Science ®Google Scholar
• REICHEN J, LE M: Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J. CM]. Invest. (1986) 78(2):448–455.
   PubMed Web of Science ®Google Scholar
• VINEL JP, CAUCANAS JP, COMBIS JM, CALES P, VOIGT JJ, PASCAL JP: Verapamil has no effect on porto-hepatic pressure gradient hepatic blood flow and elimination function of the liver in patients with liver cirrhosis. I Hepatol (1989) 8(3):302–307.
   Web of Science ®Google Scholar
• NAVASA M, BOSCH J, REICHEN J et al: Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology (1988) 8(4):850–854.
   PubMed Web of Science ®Google Scholar
• IWAO T, TOYONAGA A, IKEGAMI M etal.: Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis. Am. I Gastroenterol (1992) 87(3):326–331.
   Google Scholar
• GARCIA-PAGAN JC, FEU F, LUCA A etal.: Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. I Hepatol (1994) 20(6):792–796.
   Google Scholar
• KOSHY A, HADENGUE A, LEE SS, JIRON MI, LEBREC D: Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis.Pharmacol Ther. (1987) 42(3):295–298.
   Web of Science ®Google Scholar
• RUNYON BA: Care of patients with ascites. N Engl. J. Med. (1994) 330(5):337–342.
   PubMed Web of Science ®Google Scholar
• ••A good overview of evidence-basedmanagement of ascites in cirrhosis.
   Google Scholar
• GERBES AL: Medical treatment of ascites in cirrhosis. I Hepatol (1993) 17\(Suppl. 2):54–59.
   Google Scholar
• SALO J, GUEVARA M,FERNANDEZ-ESPARRACH G et al.:Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology(1997) 25(6):1338–1342.
   Google Scholar
• SALO J, GINES A, ANIBARRO L et al: Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin aldosterone and norepinephrine levels. Hepatology (1995) 22(2):479–487.
   PubMed Web of Science ®Google Scholar
• RUNYON BA: Refractory ascites. Semin. Liver Dis. (1993) 13(4):343–351.
   PubMed Web of Science ®Google Scholar
• GINES A, FERNANDEZ-ESPARRACH G, MONESCILLO A etal.: Randomized trial comparing albumin dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 111(4):1002–1010.
   Google Scholar
• GINES P, GUEVARA M, DE LAS HERAS D, ARROYO V: Review article: albumin for circulatory support in patients with cirrhosis. Aliment. Pharmacol Ther. (2002) 16\(Suppl. 5):24–31.
   Google Scholar
• PEREZ-AYUSO RM, ARROYO V, PLANAS R et al: Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology (1983) 84(5 Pt 1):961–968.
   Google Scholar
• FOGEL MR, SAWHNEY VK, NEAL EA, MILLER RG, KNAUER CM,GREGORY PB: Diuresis in the ascitic patient: a randomized controlled trial of three regimens. j Chu. Gastroenterol (1981) 3\(Suppl. 0:73–80.
   Google Scholar
• LI CP, LEE FY, HWANG SJ et al: Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study.Am. I Gastroenterology (2000) 95(4):1051–105.
   Google Scholar
• ANGELI P, DALLA PRIA M, DE BEI E et al: Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology (1994) 19(1):72–79.
   PubMed Web of Science ®Google Scholar
• RUNYON BA: Management of adult patients with ascites caused by cirrhosis. Hepatology (1998) 27(1):264–272.
   PubMed Web of Science ®Google Scholar
• SORT P, NAVASA M, ARROYO V et Effect of intravenous albumin on renal impairment and mortality in patients withcirrhosis and spontaneous bacterial peritonitis. N Engl. j Med. (1999) 341(6):403–409.
   PubMed Web of Science ®Google Scholar
• NAVASA M, FOLLO A, LLOVET JM etal.: Randomized comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 111(4):1011–1017.
   Google Scholar
• TERG R, COBAS S, FASSIO E et al: Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter randomized study.Hepatol (2000) 33(4):564–569.
   Web of Science ®Google Scholar
• TITO L, RIMOLA A, GINES P, LLACH J, ARROYO V, RODES J: Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology (1988) 8(1):27–31.
   PubMed Web of Science ®Google Scholar
• GINES E RIMOLA A, PLANAS R et al: Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebo-controlled trial. Hepatology (1990) 12(4 Pt 1):716–724.
   Google Scholar
• HADENGUE A, GADANO A,MOREAU R etal.: Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. j Hepatol (1998) 29(4):565–570.
   Google Scholar
• HALIMI C, BONNARD E BERNARD B etal.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.Eur. j Gastroenterol Hepatol (2002) 14(2):153–158.
   Google Scholar
• MOREAU R, DURAND F, POYNARD T etal.: Terlipressin in patients with cirrhosis and Type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 122(4):923–930.
   Google Scholar
• ORTEGA R, GINES P, URIZ J et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. Hepatology (2002) 36(4 Pt 1):941–948.
   Google Scholar
• KAFFY F, BORDERIE C, CHAGNEAU C etal.: Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. Hepatol (1999) 30(1):174.
   Google Scholar
• ANGELI P, VOLPIN R, GERUNDA G etal.: Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (1999) 29(6):1690–1697.
   Google Scholar
• GINES A, SALMERON JM, GINES P et al.: Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure.Hepatol (1993) 17(2):220–226.
   Web of Science ®Google Scholar
• BENNETT WM, KEEFFE E, MELNYK C, MAHLER D, ROSCH J, PORTER GA: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch. Intern. Med. (1975) 135(7):964–971.
   PubMedGoogle Scholar
• HOLT S, GOODIER D, MARLEY R etal.: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet (1999) 353(9149):294–295.
   Google Scholar
• VAUGHAN RB, CHIN-DUSTING JP, DUDLEY FJ, ANGUS PW: Peripheral vasodilatation following endothelin-1 infusion in patients with decompensated cirrhosis. Hepatology (2000) 32(4):403A.
   Web of Science ®Google Scholar
• SOPER CP, LATIF AB, BENDING MR: Amelioration of hepatorenal syndrome with selective endothelin-A antagonist.Lancet (1996) 347(9018):1842–1843.
   PubMed Web of Science ®Google Scholar
• VALLANCE P, MONCADA S: Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet (1991) 337(8744):776–778.
   PubMed Web of Science ®Google Scholar
• ALBILLOS A, DE LA HERA A, GONZALEZ M etal.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology (2003) 37(1):208–217.
   Google Scholar
• CHIN-DUSTING JP, RASARATNAM B, JENNINGS GL, DUDLEY FJ: Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann. Intern. Med. (1997) 127(10:985–988.
   PubMedGoogle Scholar
• RASARATNAM B, KAYE DM, JENNINGS GL, DUDLEY E CHIN-DUSTING JP: Selective intestinal decontamination ameliorates the hyperdynamic circulatory state in patients with hepatic cirhosis.Ann. Intern. Med. (In Press).
   Google Scholar
• GUYADER D, PATAT A, ELLIS-GROSSE EJ, ORCZYK GP: Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology (2002) 36(5):1197–1205.
   PubMed Web of Science ®Google Scholar
• WONG F, BLEI AT, BLENDIS LM, THULUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients withhyponatremia: a multicenter randomized placebo-controlled trial. Hepatology (2003) 37(1):182–191.
   PubMed Web of Science ®Google Scholar
• FIORUCCI S, ANTONELLI E, MORELLI 0 et al.: NCX-1000 a NO releasing derivative of ursodeoxycholic acid selectively delivers NO to the liver and protects against development of portal hypertension. Proc. Natl. Acad. Sci. USA (2001) 98(15):8897–8902.
   Google Scholar